Browsing Tag
Autoimmune Disease
12 posts
Akeso gumokimab approval strengthens China biologics push as psoriasis market heats up
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and boost its autoimmune drug strategy.
How AlloNK could challenge autologous CAR-T approaches in difficult autoimmune diseases
Can AlloNK challenge autoimmune CAR-T therapies? Explore what Artiva Biotherapeutics, Inc.’s latest data means for the future of cell therapy.
A one-time lupus reset? Why CTA313 is forcing competitors to rethink strategy
Can CTA313 disrupt lupus markets with one-time remission? Explore how Imviva Biotech is reshaping autoimmune competition.
Why selective immune homeostasis is the bigger story behind CUE-401
Cue Biopharma’s CUE-401 data points to a bigger autoimmune story. Read why selective immune homeostasis could reshape immunology pipelines.
How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race
How HB2198’s Phase 1 launch could reshape the lupus immune-reset therapy race and what it means for biotech strategy, competition, and valuation. Read more.
Innovent Biologics launches clinical trial for IBI3011 to target gout and inflammatory diseases in China
Find out how Innovent Biologics is targeting unmet needs in gout with IBI3011, a first-in-class anti-IL-1RAP antibody now in clinical trials. Read more.
Cartesian Therapeutics reports 100% lupus response signal, setting up Descartes-08 for myositis expansion
Find out how Cartesian Therapeutics achieved a 100% lupus response and is driving Descartes-08 into myositis development today.
SetPoint Medical to present new 12-month rheumatoid arthritis data at ACR 2025 ahead of U.S. launch
SetPoint Medical will present long-term RA trial data at ACR 2025, strengthening its FDA-cleared implant’s case ahead of commercial rollout. Learn more.
Analysts weigh Bristol Myers Squibb’s $1.5bn Orbital Therapeutics deal as a bold but risky pivot
Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics aims to advance in vivo CAR T for autoimmune diseases and strengthen its RNA platform.
Cabaletta Bio’s rese-cel CAR-T data at ESGCT 2025 reveal biologic activity without preconditioning in autoimmune disease
Cabaletta Bio’s ESGCT 2025 rese-cel data show early CAR-T activity without chemotherapy preconditioning — see how this could redefine autoimmune therapy.